BKU vs CNS

BKU exhibits weak financial health with a Piotroski F-Score of just 2/9, signaling significant balance sheet and profitability concerns, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite this, the stock shows strong profitability margins and consistent analyst buy recommendations, supported by a solid dividend yield and a valuation that appears reasonable relative to peers. Earnings growth is nearly flat year-over-year, and technical indicators suggest a weak short-term trend. The current price of $47.64 sits below the analyst target of $54.09 but above the conservative Graham Number of $55.72, indicating mixed value signals.

CNS exhibits a stable financial foundation with a Piotroski F-Score of 5/9 and very low debt (D/E 0.22), but it is fundamentally overvalued. The current price of $67.71 trades at a significant premium to both the Graham Number ($27.35) and the growth-based Intrinsic Value ($50.59). This valuation gap is compounded by a bearish technical trend (0/100), insider selling, and a dangerously high dividend payout ratio of 83.77%. Recent earnings performance is lackluster, with only one beat in the last four quarters.